Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Elliott

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|August 13, 2004
Radiotherapy wait times for patients with a diagnosis of invasive cancer, 1992-2000Grace M Johnston, Vicki L MacGarvie, David Elliott, et al.
International Journal of Radiation Oncology, Biology, Physics|February 4, 2022
Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung CancerAlex K Bryant, Kamya Sankar, Garth W Strohbehn, et al.
International Journal of Radiation Oncology, Biology, Physics|April 22, 2022
Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant DurvalumabAlex K Bryant, Kamya Sankar, Garth W Strohbehn, et al.
BMC Biochemistry|July 11, 2014
Application of Gaussia luciferase in bicistronic and non-conventional secretion reporter constructsChristin Luft, Jamie Freeman, David Elliott, et al.
Plos One|November 8, 2012
Defining the cause of death in hospitalised patients with acute kidney injuryNicholas M Selby, Nitin V Kolhe, Christopher W McIntyre, et al.
Journal for Immunotherapy of Cancer|June 23, 2026
Heterogeneous survival impact of immune-related adverse events in US veteransSadiq Rehmani, Luke Michael Higgins, Daria Brinzevich, et al.
Lung Cancer (Amsterdam, Netherlands)|December 13, 2021
Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancerAlex K Bryant, Kamya Sankar, Garth W Strohbehn, et al.
Journal of Leukocyte Biology|January 30, 2019
Loss of RHBDF2 results in an early-onset spontaneous murine colitisRamasatyaveni Geesala, Willow Schanz, Mikayla Biggs, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2022
De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancerAlex K Bryant, Kamya Sankar, Lili Zhao, et al.
Microorganisms|November 27, 2024
Cast from the Past? Microbial Diversity of a Neolithic Stone CircleMercedes Martín-Cereceda, Amaya de Cos-Gandoy, Richard A J Williams, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|August 13, 2004
Radiotherapy wait times for patients with a diagnosis of invasive cancer, 1992-2000Grace M Johnston, Vicki L MacGarvie, David Elliott, et al.
International Journal of Radiation Oncology, Biology, Physics|February 4, 2022
Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung CancerAlex K Bryant, Kamya Sankar, Garth W Strohbehn, et al.
International Journal of Radiation Oncology, Biology, Physics|April 22, 2022
Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant DurvalumabAlex K Bryant, Kamya Sankar, Garth W Strohbehn, et al.
BMC Biochemistry|July 11, 2014
Application of Gaussia luciferase in bicistronic and non-conventional secretion reporter constructsChristin Luft, Jamie Freeman, David Elliott, et al.
Plos One|November 8, 2012
Defining the cause of death in hospitalised patients with acute kidney injuryNicholas M Selby, Nitin V Kolhe, Christopher W McIntyre, et al.
Journal for Immunotherapy of Cancer|June 23, 2026
Heterogeneous survival impact of immune-related adverse events in US veteransSadiq Rehmani, Luke Michael Higgins, Daria Brinzevich, et al.
Lung Cancer (Amsterdam, Netherlands)|December 13, 2021
Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancerAlex K Bryant, Kamya Sankar, Garth W Strohbehn, et al.
Journal of Leukocyte Biology|January 30, 2019
Loss of RHBDF2 results in an early-onset spontaneous murine colitisRamasatyaveni Geesala, Willow Schanz, Mikayla Biggs, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2022
De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancerAlex K Bryant, Kamya Sankar, Lili Zhao, et al.
Microorganisms|November 27, 2024
Cast from the Past? Microbial Diversity of a Neolithic Stone CircleMercedes Martín-Cereceda, Amaya de Cos-Gandoy, Richard A J Williams, et al.
Pageof 8